Document:

EXHIBIT 10.31

 

CONFIDENTIAL TREATMENT REQUESTED. Confidential
portions of this document have been redacted and have been separately filed with the Commission. 

 

 

 

COLLABORATION
AGREEMENT

 

This
Collaboration Agreement (the “Agreement”) is made effective as of January 22, 2019 (the “Effective
Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon,
NH 03766 (“Adimab”), and Checkpoint Therapeutics, Inc., having an address at 2 Gansevoort Street, 9th
Floor, New York, NY 10014 (“Checkpoint”).

 

Background

 

Whereas,
Adimab is a leader in yeast-based, fully human antibody discovery and optimization using its proprietary core technology platform;

 

Whereas,
Checkpoint is a biotechnology company in the business of, among other things, developing and commercializing therapeutic products;

 

Whereas,
Adimab and Fortress collaborated on multiple Research Programs, including the PD-L1 Research Program (as defined below), and Fortress
relinquished rights to the PD-L1 Antibodies (as defined below) such that Adimab and Checkpoint may enter into this Agreement;

 

Whereas,
Checkpoint, by virtue of a previous option exercise, has a license to develop, manufacture and commercialize the PD-L1
Antibodies in accordance with the terms hereof; and

 

Now,
Therefore, in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and
valuable consideration, the receipt of which is hereby acknowledged, Adimab and Checkpoint hereby agree as follows:

 

article
1

 

DEFINITIONS.

 

The following initially
capitalized terms have the following meanings (and derivative forms of them shall be interpreted accordingly):

 

1.1          “AAA”
has the meaning set forth in Section 10.2(c)(i) (Arbitration).

 

1.2          “Adimab”
has the meaning set forth in the recitals.

 

1.3          “Adimab
Indemnitees” has the meaning set forth in Section 8.2 (Indemnification by Checkpoint).

 

1.4          “Adimab
Materials” means any tangible biological or chemical materials (including all vectors, antibodies and other Know-How
in the form of tangible biological or chemical materials) used or created by Adimab under a Research Program, including quantities
of Program Antibodies (and DNA encoding these Program Antibodies), but excluding from and after the time of Option exercise for
the relevant Target any quantities of Optioned Antibodies (and DNA encoding these Optioned Antibodies) provided to Checkpoint for
such Target.

 

     

     

    

 

1.5          “Adimab
Platform Patents” means all Patents Adimab Controls during the term of this Agreement that claim or Cover Adimab Platform
Technology. (For clarity, Adimab Platform Patents exclude Program Antibody Patents.)

 

1.6          “Adimab
Platform Technology” means (a) the discovery and optimization of antibodies via methods that include the use of synthetic
DNA antibody libraries and engineered strains of yeast, (b) all methods, materials and other Know-How used in the foregoing and
(c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b). For clarity, Adimab
Platform Technology excludes Program Antibodies, but includes technology used in the discovery and optimization of any Program
Antibody, in each case not based on the specific composition of such Program Antibody (or product containing a Program Antibody),
but based instead on the manner in which such Program Antibody was discovered or optimized under a Research Program.

 

1.7          “Adimab
Platform Technology Improvement” means all Know-How developed or discovered through or as a result of a Research Program,
and all Program Inventions (and Patents claiming them) that constitute, Cover, claim or are directed to Adimab Platform Technology,
including any and all improvements, enhancements, modifications, substitutions, alternatives or alterations to Adimab Platform
Technology.

 

1.8          “Adimab
Program Inventions” means all Program Inventions made solely by employees of, or others obligated to assign Program Inventions
to, Adimab.

 

1.9          “Affiliate”
means an entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common
control with a Party. For this purpose, “control” means the ownership of fifty percent (50%) or more of the voting
securities entitled to elect the directors or management of the entity, or the actual power to elect or direct the management of
the entity.

 

1.10        “Agreement”
has the meaning set forth in the recitals.

 

1.11        “Back-Up
Candidate” means a Product that (a) is directed to the same Target (or, with respect to a multispecific antibody, the
same set of Targets) as another Product (the “Lead Product”), and (b) has been selected by Checkpoint as a back-up
to the Lead Product for development and commercialization.

 

1.12        “Checkpoint
Indemnitees” has the meaning set forth in Section 8.1 (Indemnification by Adimab).

 

1.13        “Checkpoint
Materials” means (a) any tangible biological or chemical materials (including antigen samples and other Know-How in the
form of tangible biological or chemical materials) provided by Checkpoint to Adimab under a Research Program (other than commercial
material purchased by Checkpoint and delivered to Adimab), and (b) from and after the time of the Option exercise for a Target,
the quantities of Optioned Antibody to such Target provided to Checkpoint by Adimab under this Agreement.

 

1.14        “Checkpoint
Program Inventions” means all Program Inventions made solely by employees of, or others obligated to assign Program Inventions
to, Checkpoint.

 

    	 	2	 

     

    

 

1.15        “Commercially
Reasonable Efforts” means the level of efforts required to carry out a task in a diligent and sustained manner without
undue interruption, pause or delay; which level is at least commensurate with the level of efforts that a similarly situated biopharmaceutical
company would devote to a product of similar potential and having similar commercial and scientific advantages and disadvantages
resulting from the company’s own research efforts (i.e., explicitly ignoring the royalty, milestone and other payments due
Adimab under this Agreement), taking into account safety and efficacy; the competitiveness of alternative products; the proprietary
position of the product; pricing and reimbursement; and all other relevant commercial factors.

 

1.16       “Confidential
Information” has the meaning set forth in Section 6.1(a) (General Confidentiality Obligations).

 

1.17       “Combination
Product” means a Product (a) containing a Licensed Product together with one or more other active ingredients
(excluding antibody-drug conjugates, CAR-T products and bispecifics), or (b) marketed with one or more products, devices, pieces
of equipment or components, but sold for an integrated price (e.g., with the purchase of one product the customer gets a coupon
for the full price of the other) or for a single price.  

 

1.18       “Control”
means, with respect to any Know-How or Patent, possession by a Party, whether by ownership or license (other than pursuant to this
Agreement) of the ability to grant a license or sublicense as provided for in this Agreement without violating the terms of any
written agreement with any Third Party.

 

1.19       “Cover”
means, with respect to a particular item and a particular Patent, that such Patent claims or covers, in any of the countries of
manufacture, use, and/or sale, (a) the composition of such item, or of any product containing such item or that is made using such
item by virtue of such product containing or being made using such item; and (b) a method of making or using any of the things
referred to in (a).

 

1.20       “Dispute”
has the meaning set forth in Section 10.2(a) (Initial Dispute Resolution).

 

1.21       “Effective
Date” has the meaning set forth in the recitals.

 

1.22       “Evaluation
Term” means, with respect to each Research Program, the time period beginning at the end of the Research Term for such
Research Program and ending twenty four (24) months thereafter.

 

1.23       “Excluded
Technology” means technology (and the Patents that Cover such technology) related to:

 

(a)          product
formulation;

 

(b)          manufacturing
or production;

 

(c)          the
sequence of, or any modification to, a Program Antibody (including Patents relating to pegylation or other chemical modification)
or sequences of antibodies against a Target;

 

(d)          technology
used in activities performed by or on behalf of Checkpoint or its Licensees, including assays, in vivo testing, and modifications
to Program Antibodies;

 

    	 	3	 

     

    

 

(e)          any
Target (including any antigen representation thereof), or any mechanism of action via interaction with a Target, or antibodies
based on their interaction with a Target, or their having been tested for their activity against a Target in a biological assay;

 

(f)           the
use of Checkpoint Materials;

 

(g)          if
other than an IgG, the construct of any Product; and

 

(h)          technology
related to anything other than the manner in which Adimab discovered the antibody, the Adimab Platform, or its operation generally.

 

1.24       “Field”
means any and all uses and purposes, including, without limitation, diagnostic, prophylactic, and therapeutic uses, in humans and
animals.

 

1.25       “First
Commercial Sale” means, with respect to a Product in any country, the first sale, transfer or disposition for value or
for end use or consumption of such Product in such country after Marketing Approval for such Product has been received in such
country.

 

1.26       “Force
Majeure” means conditions beyond a Party’s reasonable control or ability to plan for, including acts of God, war,
terrorism, civil commotion, labor strike or lock-out; epidemic; failure or default of public utilities or common carriers; and
destruction of facilities or materials by fire, earthquake, storm or like catastrophe; provided, however, the payment of
invoices due and owing under this Agreement shall not be excused by reason of a Force Majeure affecting the payor.

 

1.27       “Fortress”
means Fortress Biotech, Inc., 2 Gansevoort, 9th Floor, New York, NY 10014.

 

1.28       “FTE”
means the equivalent of a full-time employee’s working days over a twelve (12) month period (taking account of normal vacations,
sick days and holidays not being considered working days), which equates to a total of one thousand eight hundred (1,800) hours
per twelve (12) month period of work performed by a fully qualified Adimab employee or consultant in a Research Program. To provide
an FTE over a given time period that is less than a year means to provide the proportionate share (corresponding to the proportion
that such time period bears to a full year) during such time period of a full year’s FTE. In no event shall the work over
the course of a year of one individual person account for more than one (1) FTE year.

 

1.29       “FTE
Rate” means * dollars ($*) per FTE.

 

1.30       “Indemnify”
has the meaning set forth in Section 8.1 (Indemnification by Adimab).

 

1.31       “Joint
Inventions” means any and all Program Inventions made jointly by employees of, or others obligated to assign Program
Inventions to, each of Adimab and Checkpoint.

 

 

		*	Confidential material redacted and filed separately with
the Commission.

 

    	 	4	 

     

    

 

1.32       “Joint
Serendipitous Inventions” means all Joint Inventions other than those claimed by Program Antibody Patents or constituting
Adimab Platform Technology Improvements.

 

1.33       “Know-How”
means all technical information and know-how, including (i) inventions, discoveries, trade secrets, data, specifications, instructions,
processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise
and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their
manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture,
formulations containing them or compositions incorporating or comprising them, and (ii) all data, instructions, processes, formula,
strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical,
analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines.

 

1.34       “Lead
Product” has the meaning set forth in Section 1.11 (Back-Up Candidate).

 

1.35       “License
Agreements” has the meaning set forth in Section 9.6 (Additional Effects of Termination).

 

1.36       “Licensee”
means a Third Party to whom Checkpoint has granted, directly or indirectly, rights to research, develop, manufacture, and/or commercialize
Program-Benefited Antibodies; provided, however, that Licensees shall exclude fee-for-service contract research organizations
or contract manufacturing organizations acting in such capacity. For clarity, licensees of the rights assigned to Checkpoint by
Adimab and sublicensees of the license granted by Adimab to Checkpoint pursuant to Section 3.2 (Commercial Rights) shall
be Licensees.

 

1.37       “Losses”
has the meaning set forth in Section 8.1 (Indemnification by Adimab).

 

1.38       “Marketing
Approval” each means, with in any given country, approval to market a Product legally as a drug or biologic, including
approval of a Biologic License Application (as defined in the U.S. Federal Food, Drug and Cosmetics Act and the regulations promulgated
thereunder (21 C.F.R. §§ 600-680) in the United States, or approval of a comparable filing in the United States or any
other jurisdiction. Pricing approval need not be obtained in order for Marketing Approval to be achieved.

 

1.39       “Milestone
Event” has the meaning set forth in Section 4.4 (Milestone Events).

 

1.40       “Milestone
Payment” has the meaning set forth in Section 4.4 (Milestone Events).

 

1.41       “Net
Sales” means the gross amounts invoiced for a Product by Checkpoint, its Affiliates and Licensees for sales or other
commercial disposition of such Product to a Third Party purchaser, less the following:

 

(a)           trade
and quantity discounts (other than early pay cash discounts) actually allowed with respect to such sales which effectively reduce
the selling price and are appropriately deducted from sales under appropriate accounting principles, consistently applied;

 

(b)          discounts,
returns, rebates, chargebacks and other allowances actually allowed with respect to such sales;

 

    	 	5	 

     

    

 

(c)           retroactive
price reductions that are actually allowed or granted;

 

(d)          deductions
to the gross invoice price of Product imposed by regulatory authorities or other governmental entities;

 

(e)          Shipping,
handling, freight, postage, insurance and transportation charges.

 

(f)           any
tax imposed on the production, sale, delivery or use of the Product, including, without limitation, sales, use, excise or value
added taxes, or the annual fee imposed on the pharmaceutical manufacturers by the U.S. government; and

 

(g)          a
fixed amount equal to one and one-half percent (1.5%) of the amount invoiced to cover bad debt, early payment cash discounts, transportation
and insurance

 

Products are considered
“sold” when billed, invoiced or payment is received, whichever comes first.

 

Notwithstanding the foregoing, Net Sales shall not include,
and shall be deemed zero with respect to Products provided by or on behalf of Checkpoint, an Affiliate or a Licensee to Checkpoint,
an Affiliate or a Licensee for purposes of resale, provided such resale is included in Net Sales.

 

If any Optioned Antibody
is sold as part of a Combination Product, the Net Sales for such Optioned Antibody shall be determined on a country-by-country
basis as follows: the Net Sales of the Combination Product (prior to application of the following adjustment) shall be multiplied
by the fraction A/(A+B), where A is the net selling price in such country of the Product with only the Optioned Antibody (i.e.,
without the additional active ingredient in the Combination Product) if sold separately for the same dosage (or form) as contained
in the Combination Product, and B is the net selling price in such country of any other active ingredients in the combination if
sold separately for the same dosage (or form) as contained in the Combination Product.  All net selling prices of the elements
of such end-user product shall be calculated as the average net selling price of the said elements during the applicable accounting
period for which the Net Sales are being calculated.  In the event that, in any country, no separate sale of either such above-designated
Product (containing only such Optioned Antibody and no other active ingredients) or any one or more of the active ingredients included
in such Combination Product are made during the accounting period in which the sale was made or if the net selling price for an
active ingredient cannot be determined for an accounting period, Net Sales for purposes of determining payments under this Agreement
shall be calculated by multiplying the sales price of the Combination Product by the fraction C/(C+D) where C is the standard fully-absorbed
manufacturing cost of the Optioned Antibody portion of the combination, and D is the standard fully-absorbed manufacturing cost
of the other active ingredients included in the Combination Product, as determined by Checkpoint using its standard accounting
procedures consistently applied. In the event that the standard fully-absorbed manufacturing cost of the Optioned Antibody and/or
the other active ingredients included in such Combination Product cannot be determined, Net Sales allocable to the Combination
Product in each such country shall be determined by mutual agreement (such agreement to not be unreasonably withheld) reached in
good faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining the
same that takes into account, on a country-by-country basis, all relevant factors (including variations in potency, the relative
contribution of each active ingredient in the combination and relative value to the end user of each active ingredient).

 

    	 	6	 

     

    

 

1.42       “Optimized
Antibody” means an antibody resulting from the optimization, pursuant to a Research Plan, by Adimab of Checkpoint Antibody.
For the avoidance of doubt, any activities conducted by Adimab under a Research Plan using an antibody provided by Checkpoint shall
be deemed “optimization.” Optimized Antibodies shall themselves be Program Antibodies. For clarity, the PD-L1 Antibodies
are Optimized Antibodies.

 

1.43       “Optimized
Product” means any Product that contains one or more Optimized Antibodies and does not contain Program Antibodies other
than Optimized Antibodies.

 

1.44       “Option”
has the meaning set forth in Section 3.2(a) (Option).

 

1.45       “Option
Fee” has the meaning set forth in Section 4.3 (Option Fee).

 

1.46       “Optioned
Antibody” means any Program Antibody selected by Checkpoint pursuant to Section 3.2(a) (Option), and any Program-Benefited
Antibody generated from such selected Program Antibody.

 

1.47       “Optioned
Program Antibody Patents” means those Program Antibody Patents that solely Cover Optioned Antibodies.

 

1.48       “Optioned
Program Antibody Know-How” means Know-How included in Program Inventions that relates solely to Optioned Antibodies.

 

1.49       “Original
Fortress Agreement” means that certain Collaboration Agreement between Fortress and Adimab dated June 29, 2015.

 

1.50       “Party”
means Adimab or Checkpoint.

 

1.51       “Patent”
means any patent application or patent anywhere in the world, including all of the following categories of patents and patent applications,
and their foreign equivalents: provisional, utility, divisional, continuation, continuation-in-part, and substitution applications;
and utility, re-issue, re-examination, renewal and extended patents, and patents of addition, and any Supplementary Protection
Certificates, restoration of patent terms and other similar rights.

 

1.52       “PD-L1
Antibodies” means the Program Antibodies generated in the PD-L1 Research Program.

 

1.53       “PD-L1
Research Program” means that Research Program designed to generate Program Antibodies against the Target known as programmed
death-ligand 1 (“PD-L1”).

 

1.54       “Phase
I Trial” means a human clinical trial (whether a phase la or a phase lb trial) in any country of the type described in
21 C.F.R. §312.21(a), or an equivalent clinical study required by a Regulatory Authority outside of the United States.

 

1.55       “Phase
II Trial” means a human clinical trial conducted in any country of the type described in 21 C.F.R. §312.21(b), or
an equivalent clinical study required by a Regulatory Authority outside of the United States.

 

1.56       “Phase
III Trial” means a human clinical trial in any country of the type described in 21 C.F.R. § 312.21(c), or an equivalent
clinical study required by a Regulatory Authority outside the United States. For purposes of this Agreement, a human clinical trial
that combines elements of a Phase II Trial and a Phase III Trial (a Phase II/III trial) shall be deemed a Phase III Trial.

 

    	 	7	 

     

    

 

1.57       “Product”
means a pharmaceutical preparation in any form that comprises or contains one or more Program-Benefited Antibodies (whether or
not such product is currently under evaluation for safety, efficacy, or other factors).

 

1.58       “Program
Antibody” means any PD-L1 Antibody. It is understood and agreed that even if Adimab delivers nucleic acid sequences or
amino acid sequences to Checkpoint instead of protein samples, antibodies encoded by such nucleic acid sequences or amino acid
sequences are Program Antibodies, in addition to antibodies samples of which are physically delivered to Checkpoint under this
Agreement.

 

1.59       “Program
Antibody Know-How” means Know-How (a) included in Program Inventions that relates to Optioned Antibodies, excluding Optioned
Program Antibody Know-How and (b) does not relate to Adimab Platform Technology or Adimab Platform Technology Improvements.

 

1.60       “Program
Antibody Patents” means Patents that (a) Cover a Program-Benefited Antibody or any Product and (b) do not Cover Adimab
Platform Technology or Adimab Platform Technology Improvements.

 

1.61       “Program
Assets” has the meaning set forth in Section 9.6 (Additional Effects of Termination).

 

1.62       “Program-Benefited
Antibody” means any Program Antibody and any modified or derivative form of any such Program Antibody (including an scFv)
created by or on behalf of Checkpoint or its Licensees, including any fragment thereof, pegylated version thereof (whether or not
including amino acid changes) and including chemically modified versions (including associated amino acid substitutions) of a Program
Antibody, and including an antibody designed or derived using the sequence of any Program Antibody, nucleotide coding for it, any
cell line or cellular or bacterial expression system or vector expressing any Program Antibody or incorporating the nucleotide
coding for a Program Antibody.

 

1.63       “Program
Inventions” means any invention that is conceived and/or first reduced to practice in the course of or as a result of
the activities conducted under this Agreement (including in exercise of a license under this Agreement) or as a result of the use
of Confidential Information exchanged hereunder. For clarity, Program Inventions include all Know-How made, developed, invented
or discovered by employees, contractors or agents of either Party or of both Parties pursuant to this Agreement.

 

1.64       “Program
Patent” means any Patent Covering a Program Invention.

 

1.65       “Regulatory
Assets” has the meaning set forth in Section 9.6 (Additional Effects of Termination).

 

1.66       
“Regulatory Authority” means the FDA or any counterpart of the FDA outside the United States, or other national,
supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity
with authority over the distribution, importation, exportation, manufacture, production, use, storage, transport, clinical testing
or sale of a pharmaceutical product (including a Product), which may include the authority to grant the required reimbursement
and pricing approvals for such sale.

 

    	 	8	 

     

    

 

1.67       [Intentionally
Omitted.]

 

1.68       “Research
Plan” means the research plan to be agreed upon by the Parties with respect to a Target in accordance with Section 2.1
(Research Programs) hereof.

 

1.69       “Research
Program” means each program of research conducted under this Agreement in accordance with a Research Plan.

 

1.70       “Research
Term” means the period beginning on the Effective Date and ending, on a Research Program-by-Research Program basis, when
Adimab delivers final antibodies under a Research Plan; provided, however, that in the event that Adimab is unable to deliver
antibodies pursuant to a Research Plan within one (1) year of commencing work on such Research Plan, then either Party may terminate
the Research Term with respect to such Research Program at such point.

 

1.71       “Royalty
Payment” has the meaning set forth in Section 4.5(a) (Royalty Payments).

 

1.72       “Royalty
Term” means, on a Product-by-Product and country-by-country basis, the term ending at the later to occur of (a) the expiration
of the last Valid Claim Covering the Product in the country in which such Product is manufactured or sold, or (b) twelve (12) years
after the First Commercial Sale of such Product in such country.

 

1.73       “Senior
Executive Discussions” has the meaning set forth in Section 10.2(a) (Initial Dispute Resolution).

 

1.74       “Sublicense
Agreement” has the meaning set forth in Section 3.2 (Licenses).

 

1.75       “Tangible
Assets” has the meaning set forth in Section 9.6 (Additional Effects of Termination).

 

1.76       “Target”
means PD-L1.

 

1.77       “Third
Party” means an entity other than a Party or a Party’s Affiliates.

 

1.78       “Third
Party Claims” has the meaning set forth in Section 8.1 (Indemnification by Adimab).

 

1.79       “Third
Party Patent Licenses” means Patent licenses obtained by Checkpoint after Checkpoint determines in good faith that one
or more such Patent licenses from Third Parties are reasonably required by Checkpoint because such Patents Cover the way in which
Program Antibodies were discovered or optimized using Adimab Platform Technology under a Third Party Patent Covering the Adimab
Platform Technology, in order to avoid Third Party claims of patent infringement relating to the discovery or optimization of a
Optioned Antibody, which claims are reasonably believed by Checkpoint to be reasonably likely not to be dismissed at summary judgment
and are reasonably likely to succeed overall. For clarity, Third Party Patent Licenses explicitly excludes licenses to any Excluded
Technology.

 

    	 	9	 

     

    

 

1.80       “Transferred
Assets” has the meaning set forth in Section 9.6 (Additional Effects of Termination).

 

1.81       
“Valid Claim” means a claim of a Patent, which claim (i) is issued and unexpired and has not been found to be
unpatentable, invalid or unenforceable by a court or other authority having jurisdiction, from which decision no appeal is taken,
will be taken or can be taken; or (ii) is pending and has not been finally abandoned or finally rejected and has been pending for
no more than eight (8) years.

 

1.82       References
in the body of this Agreement to “Sections” refer to the sections of this Agreement. The terms “include,”
“includes,” “including” and derivative forms of them shall be deemed followed by the phrase “without
limitation” regardless of whether such phrase appears there (and with no implication being drawn from its inconsistent inclusion
or non-inclusion).

 

1.83       To
avoid doubt, the term “antibody” as used everywhere else in this Agreement includes both full-length antibodies, fragments
thereof, and chemically modified versions thereof (including pegylated versions and regardless of whether containing amino acid
substitutions), all of the foregoing whether naturally occurring, artificially produced, raised in an artificial system, or created
through modification of an antibody produced in any of the foregoing ways or otherwise, and whether represented by physical material,
nucleic acid sequences, or amino acid sequences.

 

article
2

 

RESEARCH PROGRAMS.

 

2.1         Research
Programs.

 

(a)          Research
Plans. As of the Effective Date, the Parties do not intend to collaborate on additional Research Programs, provided that the
Research Program established under the Original Fortress Agreement with respect to PD-L1 and the PD-L1 Antibodies shall be deemed
the Research Program (and the Research Plan established thereunder with respect thereto shall be deemed the Research Plan) for
purposes of this Agreement.

 

2.2         Project
Management.

 

(a)          Alliance
Managers. Each Party shall designate in writing within thirty (30) days after signing this Agreement an “Alliance Manager”
to be the primary contact for such Party. The Alliance Manager shall be responsible for managing communications between the Parties
with respect to a Research Program, including responsibility for scheduling teleconferences.

 

2.3         Reports;
Records.

 

(a)          By
Adimab. During the applicable Research Term, at the junctures specified in the applicable Research Plan, Adimab shall provide
written reports to Checkpoint regarding the Research Plan. Notwithstanding the foregoing or anything express or implied anywhere
in this Agreement, Adimab shall not be required to disclose any Adimab Platform Technology or Adimab Platform Technology Improvements
to Checkpoint. Adimab shall maintain records, in reasonable scientific and technical detail and in a manner appropriate for patent
purposes, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance
of a Research Program. In the event that such records and data include disclosure of Adimab Platform Technology or Adimab Platform
Technology Improvements, Adimab may redact those portions that would disclose Adimab Platform Technology or Adimab Platform Technology
Improvements prior to any review or inspection by Checkpoint.

 

    	 	10	 

     

    

 

(b)          By
Checkpoint. During the applicable Research Term, at the junctures set forth in the applicable Research Plan, Checkpoint shall
provide written reports to Adimab which provide any data Checkpoint is required to provide under the applicable Research Plan.

 

2.4         Use
of Adimab Materials. With respect to each Target, Checkpoint shall only use Adimab Materials (a) as is necessary to conduct
a Research Program during the Research Term and the Evaluation Term, (b) pursuant to the license granted under Section 3.1(a) (Research
License to Checkpoint) of this Agreement while such license is in effect, (c) to generate and test Program-Benefited Antibodies
in accordance with Section 9.3 (Commitments Regarding Program-Benefited Antibodies) and (d) in connection with the exercise
of its rights under Section 3.2(b). Checkpoint shall not use Adimab Materials for any other purposes. For clarity, this means that,
except as specified pursuant to the foregoing sentence, Checkpoint shall not (i) provide Adimab Materials to any Third Party, or
(ii) use any Program-Benefited Antibodies or Adimab Materials, or information related thereto (including the sequences thereof),
for any purpose other than to research and develop antibodies that will be milestone- and royalty-bearing to Adimab hereunder.
For clarity, the “sequence” of an antibody includes the amino acid sequence of the antibody and the corresponding nucleic
acid sequences. Adimab acknowledges and agrees that upon receipt of Program Antibodies, Checkpoint may conduct testing on such
Program Antibodies to optimize such Program Antibodies (and, to avoid doubt, the optimized versions thus created shall be Program-Benefited
Antibodies).

 

Adimab retains title
to the Adimab Materials, including all quantities of Program Antibodies that it provides under a Research Program, including during
the Evaluation Term. Such quantities of Program Antibodies are (i) for use solely in assessing whether to exercise the Option for
the applicable Target, and (ii) shall not be used in humans or for any commercial purpose. Should Checkpoint not exercise its Option
as described in Section 3.2(a) (Option), Checkpoint shall return to Adimab or destroy any Program-Benefitted Antibodies
in its possession on expiration of the Evaluation Term for such Target. Without limiting the generality of the foregoing, during
the Evaluation Term and after expiration of the Options, if unexercised, Checkpoint shall not provide Program-Benefitted Antibodies
to Third Parties. Notwithstanding the foregoing, should Checkpoint exercise the Option for a given Target, all right, title and
interest in and to those Program-Benefitted Antibodies shall belong to and vest in Checkpoint (subject to the terms and conditions
of this Agreement with respect to Program-Benefited Antibodies, including Section 9.3 (Commitments Regarding Program-Benefited
Antibodies) hereof).

 

2.5       Use
of Checkpoint Materials. Adimab shall use the Checkpoint Materials solely to perform the Research Program for the applicable
Target. Adimab shall not transfer or otherwise provide the Checkpoint Materials to any Third Party. Adimab shall not use Checkpoint
Materials for any other purposes. For clarity, this means that, except as specified pursuant to the foregoing sentence, Checkpoint
retains title to the Checkpoint Materials that it provides under a Research Program. Within ninety (90) days after the Research
Term for such Target ends, Adimab will return to Checkpoint or destroy any remaining Checkpoint Materials (at Checkpoint’s
direction).

 

    	 	11	 

     

    

 

2.6         Certain
Restrictions on the Use of Antibodies.

 

(a)          Adimab
Restrictions. Adimab shall not provide any Third Party with any Program Antibody delivered to Checkpoint. Adimab shall not
deliver to Checkpoint as a Program Antibody any antibody previously delivered to a Third Party.

 

To avoid doubt and
notwithstanding anything to the contrary in this Agreement:

 

(i)       nothing
herein shall prevent Adimab from licensing or transferring some or all of the Adimab Platform Technology and/or Adimab Platform
Technology Improvements to a Third Party (including technical support in connection therewith) nor shall anything herein require
Adimab to in any way limit the use of the Adimab Platform Technology and/or Adimab Platform Technology Improvements by Adimab or
a Third Party; and

 

(ii)      nothing
herein shall require Adimab to physically remove from its libraries, or to prevent from being included in future libraries, any
Program-Benefited Antibodies. Adimab hereby reserves the right for Adimab, its Affiliates, and those deriving rights from them
(a) to include Program-Benefited Antibodies in antibody library(ies) transferred or licensed by Adimab to Third Parties (including
the transfer of physical possession of samples of Program-Benefited Antibodies to a Third Party as part of such transactions) and
(b) to conduct any activity with respect to Program-Benefited Antibodies that are not Optioned Antibodies if Adimab (or such other
party) arrives at such Program-Benefited Antibodies independent from the activities performed under a Research Plan and in a manner
fully compliant with Adimab’s other covenants and obligations under this Agreement; provided, however, that, except
as permitted by Section 6.7 (Certain Data) in no event shall Adimab disclose to any Third Party, or otherwise directly or
indirectly exploit, any Confidential Information of Checkpoint, including Confidential Information regarding the relationship between
the Target and Program-Benefited Antibodies and the characterization of Program Antibodies by Adimab.

 

(b)          Checkpoint
Restrictions. Checkpoint hereby covenants that it, its Affiliates and its Licensees shall not seek to or actually research,
develop or commercialize any Program-Benefited Antibody, or product containing the foregoing (other than the activities permitted
hereunder during the Research Term and the Evaluation Term for the purpose of determining whether or not to exercise the Option
for such Target) except as Optioned Antibodies and Products under this Agreement.

 

article
3

 

LICENSES; OPTION; DEVELOPMENT
& COMMERCIALIZATION

 

3.1         Mutual
Research Program Licenses.

 

(a)          Research
License to Checkpoint. During the Research Term and Evaluation Term for each Research Program, Adimab hereby grants Checkpoint
a non-exclusive, non-sublicensable license with respect to the Target that is the subject of such Research Program under the Adimab
Platform Patents and Program Antibody Patents to perform research in the Field, including for Checkpoint to perform Checkpoint’s
responsibilities under the Research Plan and this Agreement for such Target. For clarity, the license to Checkpoint excludes the
right to (i) discover or optimize antibodies using the Adimab Platform Technology or Adimab Platform Technology Improvements, or
(ii) use Program-Benefited Antibodies or Adimab Materials to (a) screen for other antibodies’ activity vis-à-vis the
applicable Target or (b) design other antibodies (in the case of either (a) or (b), other than Program-Benefited Antibodies that
will be milestone- and royalty-bearing to Adimab under this Agreement).

 

    	 	12	 

     

    

 

(b)          Research
License to Adimab. During the Research Term and Evaluation Term for each Research Program, Checkpoint hereby grants to Adimab
a non-exclusive, nontransferable (except in connection with a permitted assignment of this Agreement) license with respect to such
Target under all Patents and Know-How Controlled by Checkpoint which Cover the Targets (including any that so relate by claiming
antibodies directed to the Targets or a mechanism of action via the Targets) or any Checkpoint Materials provided to Adimab, solely
to perform Adimab’s responsibilities as provided for in the applicable Research Plan.

 

3.2         Commercial
Rights.

 

(a)          Option.
On April 10, 2017, Checkpoint, via Fortress, exercised the exclusive option (each, an “Option”) to obtain the
licenses of Section 3.2(b) (Development and Commercialization License and Assignment) for the PD-L1 Antibodies and the PD-L1
Antibodies are the “Optioned Antibodies.”

 

(b)          Development
and Commercialization License and Assignment.

 

(i)       Assignment.
Adimab hereby, effective as of the Effective Date, assigns to Checkpoint, subject to the terms and conditions of this Agreement,
all right, title and interest in and to Optioned Program Antibody Know-How and Optioned Program Antibody Patents.

 

(ii)      License.
Adimab hereby, effective as of the Effective Date, grants to Checkpoint a worldwide, royalty-bearing, sublicenseable (solely as
provided in Section 3.2(b)(iii) (Licensees)) license under the Adimab Platform Patents, Program Antibody Know-How and Program
Antibody Patents, if any, which are not assigned to Checkpoint pursuant to Section 3.2(b)(i) (Assignment), in the Field,
to research, develop, have developed, make, have made, use, sell, offer to sell, import and export the Optioned Antibodies and
Products during the term of this Agreement. Such license shall be non-exclusive under the Adimab Platform Patents and exclusive
under Program Antibody Know-How and the Program Antibody Patents. For clarity, the license to Checkpoint excludes the right to
(i) discover or optimize antibodies using the Adimab Platform Technology or Adimab Platform Technology Improvements, or (ii) use
Program-Benefited Antibodies or Adimab Materials to (a) screen for other antibodies’ activity vis-à-vis the applicable
Target or (b) design other antibodies (in the case of either (a) or (b), other than Program-Benefited Antibodies that will be milestone-
and royalty-bearing to Adimab under this Agreement).

 

(iii)     Licensees.
Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b) (Development and Commercialization
License and Assignment) shall be made solely pursuant to agreements (“Sublicense Agreements”) that are consistent
with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable
terms of this Agreement, including Section 9.3 (Commitments Regarding Program-Benefited Antibodies) hereof. Checkpoint shall
remain responsible for all payments and other performance obligations due under this Agreement, notwithstanding any license or
sublicense that it may grant.

 

    	 	13	 

     

    

 

3.3         Diligent
Development and Commercialization. Checkpoint shall use Commercially Reasonable Efforts to clinically develop, seek Marketing
Approval for, and launch and actively commercialize at least one (1) Program Antibody discovered in each Research Program for which
it exercises the Option. Annually, Checkpoint will provide Adimab with a written report of Product progress in development and
commercialization, Checkpoint’s activities in that regard. If requested by Adimab, Checkpoint shall meet via teleconference
with Adimab to discuss such report at least annually at a time mutually agreed upon by Checkpoint and Adimab.

 

3.4         No
Implied Licenses. Other than the licenses, options and assignments explicitly set forth in this Article 3 (Licenses; Option;
Development & Commercialization) or in Article 5 (Intellectual Property), neither Party grants any intellectual
property licenses, options or assignments to the other Party under this Agreement. This Agreement does not create any implied licenses.

 

3.5          Covenant
Not to Exceed License. Each Party hereby covenants that it shall not practice any Patent or item of Know-How licensed to it
under this Agreement outside the scope of the license to such Party set forth in this Agreement (or any subsequent agreement between
the Parties providing for an additional license under such Patent or item of Know-How). For the avoidance of doubt, Checkpoint
will not research, develop, manufacture or commercialize Optioned Antibodies except as Products under this Agreement.

 

3.6         Bankruptcy
Code. If this Agreement is rejected by a Party as a debtor under Section 365 of the United States Bankruptcy Code or similar
provision in the bankruptcy laws of another jurisdiction (the "Code"), then, notwithstanding anything else in this Agreement
to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement by the Party in bankruptcy to
the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (or
similar provision in the bankruptcy laws of the jurisdiction), licenses of rights to "intellectual property" as defined
under Section 101(35A) of the United States Bankruptcy Code (or similar provision in the bankruptcy laws of the jurisdiction).
The Parties agree that a Party that is a licensee of rights under this Agreement shall retain and may fully exercise all of its
rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against a Party under the Code,
the other Party shall be entitled to a complete duplicate of, or complete access to (as such other Party deems appropriate), any
such intellectual property and all embodiments of such intellectual property, if not already in such other Party's possession,
shall be promptly delivered to such other Party (a) upon any such commencement of a bankruptcy proceeding upon written request
therefor by such other Party, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement
or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the bankrupt Party upon written
request therefor by the other Party. The foregoing provisions of this Section 3.6 are without prejudice to any rights a Party may
have arising under the Code.

 

article
4

 

FINANCIAL TERMS.

 

4.1         Technology
Access Fee. There is no technology access fee hereunder.

 

4.2         Research
Stage Fees.

 

    	 	14	 

     

    

 

(a)          Research
Funding. For each Research Plan, Checkpoint shall pay Adimab, within thirty (30) days of completion of each calendar quarter,
an amount equal to * percent (*%) of the actual FTEs expended by Adimab on the Research Programs during such calendar quarter
(at the FTE Rate).

 

(b)          Technical
Milestones.

 

(i)       [Intentionally
Omitted] 

 

(ii)       Technical
Milestone II. On a Research-Program-by-Research Program basis, Checkpoint shall pay Adimab * dollars ($*) within thirty (30)
days of Adimab’s delivery to Checkpoint of a panel of Program Antibodies meeting the criteria identified in the applicable
Research Plan as the “Technical Milestone II Criteria”. Adimab and Checkpoint hereby acknowledge that such technical
milestone payment with respect to the PD-L1 Research Program has, as of the Effective Date, already been paid in full.

 

4.3         Option
Fee. In order to exercise the Option under Section 3.2(a) (Option) for a Research Program, Checkpoint shall pay to
Adimab a non-creditable, nonrefundable option exercise fee of * dollars ($*) for each such Research Program (each, an “Option
Fee”) plus any unpaid Technical Milestone with respect to such Research Program; provided, however, that such
amount shall be reduced to * dollars ($*) with respect to the third Option exercised hereunder and each Option exercised thereafter.
Adimab and Checkpoint hereby acknowledge that the Option Fee with respect to the PD-L1 Research Program and the Program Antibody
has, as of the Effective Date, already been paid in full.

 

4.4          Milestone
Payments.

 

(a)          Milestone
Events. On a Product-by-Product basis, Checkpoint shall report in writing to Adimab the achievement of each event (each, a
“Milestone Event”) and pay the corresponding milestone payment (each, a “Milestone Payment”)
to Adimab, each within thirty (30) days after the achievement of the corresponding Milestone Event in the following table:

 

	
        Milestone
        Event
	
        Milestone
        Payment

	*	*
	*	*
	*	*
	*	*
	*	*
	*	*

 

Adimab and Checkpoint hereby acknowledge that the first milestone
payment in the table above with respect to * has, as of the Effective Date, already been paid in full with respect to the Program
Antibody.

 

 

		*	Confidential material redacted and filed separately with
the Commission.

 

    	 	15	 

     

    

 

Milestones Payments are
payable one time per Product, the first time each is achieved for such Product. If a later-stage clinical Milestones Event is achieved
for any Product without one or more earlier-stage clinical Milestone Events having been achieved for that Product, then Checkpoint
shall pay the Milestone Payment(s) for such previous clinical Milestone Event(s) along with the payment for the most recently achieved
Milestone Event. If a Milestone Event related to filing for Marketing Approval is achieved without one or more of the clinical
Milestone Events being achieved, then Checkpoint shall pay the Milestone Payment(s) for such previous clinical Milestone Event(s)
along with the payment for the first Milestone Event related to filing for Marketing Approval.

 

(b)          Back-Up
Candidates. In the event that a Milestone Event that was already achieved with respect to a Lead Product is also achieved with
respect to a Back-Up Candidate to such Lead Product prior to receipt Marketing Approval for the Lead Product, then Checkpoint’s
obligation to pay the corresponding Milestone Payment with respect to the achievement of the applicable milestone event with respect
to such Back-Up Candidate shall be deferred until receipt of marketing approval of the Lead Product. If Checkpoint continues to
develop such Back-Up Candidate after receipt of Marketing Approval for the Lead Product, all deferred Milestone Payments for such
Back-Up Candidate shall become payable within thirty (30) days after receipt of such Marketing Approval and all subsequent Milestone
Payments for such Back-Up Candidate shall be payable within ten (10) days after achievement of the corresponding Milestone Event
with respect to such Back-Up Candidate. If Checkpoint promptly discontinues all development activities with respect to a Back-Up
Candidate upon Marketing Approval of the Lead Product and provides Adimab with written notice thereof within thirty (30) days after
such Marketing Approval, Checkpoint will not be obligated to pay the deferred Milestone Payments for such Back-Up Candidate. If
Checkpoint continues to develop such Back-Up Candidate after discontinuation of development of the Lead Product (but prior to Marketing
Approval of such Lead Product), Checkpoint will not be obligated to pay the deferred Milestone Payments for such Back-Up Candidate,
but all Milestone Payments for Milestone Events achieved with respect to such Back-Up Candidate that were not paid to Adimab with
respect to such Lead Product shall be payable within ten (10) days after achievement of the corresponding Milestone Event.

 

(c)          Optimized
Products. Notwithstanding the foregoing, Milestone Payments made with respect to Optimized Products shall be * percent (*%)
of the amounts that would otherwise be due pursuant to Section 4.4(a) (Milestone Payments).

 

4.5         Royalties.

 

(a)          Royalty
Payments. As to each Product sold during the applicable Royalty Term, on a Product-by-Product basis, Checkpoint shall pay Adimab
the following royalties, based on the royalty rate applicable to the relevant portion of annual worldwide Net Sales for such Product
(“Royalty Payments”):

 

	Portion of Worldwide Calendar Year Net Sales	Royalty Rate
	*	* percent (*%)
	*	* percent (*%)

 

 

		*	Confidential material redacted and filed separately with
the Commission.

 

    	 	16	 

     

    

 

(b)          Optimized
Products. Notwithstanding the foregoing, Royalty Payments made with respect to Optimized Products shall be * percent (*%) of
the amounts that would otherwise be due pursuant to Section 4.5(a) (Royalty Payments).

 

(c)          Royalty
Term. On a Product-by-Product and country-by-country basis, upon expiration of the Royalty Term for a Product in a country,
the rights, licenses and sublicenses granted to Checkpoint hereunder with respect to such Product in such country shall continue
in effect but become fully paid-up, royalty-free and perpetual.

 

(d)          Royalty
Buy-Down.

 

(i)       Royalty
Buy-Down Prior to Phase III. On a Product-by-Product basis, Checkpoint, at its sole option any time prior to the dosing of
the first patient in the first Phase III Trial, may elect to reduce the royalty owed to Adimab pursuant to Section 4.5(a) (Royalty
Payments) to * percent (*%) of aggregate worldwide Net Sales by paying Adimab a one-time fee equal to * dollars ($*).

 

(ii)       No
Royalty Buy-Down After Commencement of Phase III Trial. If the royalty buy-down option has not been exercised at the time of
dosing of the first patient in a Phase III Trial, the royalty buy-down option shall then expire.

 

(e)          Adjustment
for Third Party IP. If Checkpoint enters into any Third Party Patent Licenses, then * percent (*%) of the net sales royalties
actually paid to the Third Party under the Third Party Patent License with respect to Net Sales of any given Product in any given
calendar quarter in any given country may be offset against the Royalty Payment, if any, that would otherwise have been payable
to Adimab with respect to such same Net Sales; provided, however, that in no event shall the royalty owed to Adimab be
reduced by more than * percent (*%) than the payment which would otherwise be due hereunder. It is understood, agreed and acknowledged
that Adimab’s allowing Checkpoint to claim the credit of this Section 4.5(e) (Adjustments for Third Party IP) as
to any particular Third Party Patent License: (a) does not mean Adimab believes that the licensed Patents were infringed or Cover
any aspect of the discovery or optimization work by Adimab; (b) does not mean Adimab agrees with Checkpoint’s opinion as
to the likelihood of success of a claim of such infringement or Coverage; (c) does not mean that Adimab believes Checkpoint’s
opinion as to any of the foregoing is reasonable; and (d) is not, will not be, and shall not be under any circumstances construed
as an admission of any kind. Adimab may have many reasons not to challenge any given assertion of the credit of this Section 4.5(e)
(Adjustment for Third Party IP) by Checkpoint, including: (1) maintaining good relations with a counterparty; (2) an assessment
that the costs of the credit are outweighed by the benefits of Checkpoint having a license in place that makes it feel comfortable
to proceed with the Product (resulting in a greater likelihood of milestones and royalties being paid to Adimab); (3) resource
limitations that make it impracticable to challenge Checkpoint’s assertion of such credit even though Adimab may disagree
whether this is proper; and (4) other reasons other than thinking that the relevant Patents Cover or were infringed.

 

 

		*	Confidential material redacted and filed separately with
the Commission.

 

    	 	17	 

     

    

 

(f)           No
Challenge to Royalty Term. Checkpoint, on behalf of itself, its Affiliates and its Licensees, hereby agrees not to challenge
the length of the Royalty Term, including through the assertion that the Royalty Term should be reduced to less than twelve (12)
years as a result of the lack of a Valid Claim Covering the relevant Product. Checkpoint agrees that if Checkpoint, its Affiliates
or its Licensees attempt to assert any such claim, then: (a) the royalty rate applicable to payments due to Adimab under this Agreement
shall automatically be retroactively adjusted to a rate twice the previously-applicable rate, and Checkpoint shall make a payment
to Adimab of such amount (including accrued interest) within fifteen (15) days of asserting such claim; and (b) Checkpoint shall
reimburse Adimab on a monthly basis (within fifteen (15) days after the end of the calendar month) for all Adimab legal costs in
connection with assessing, responding to and/or defending against such assertion in such calendar month. Checkpoint hereby irrevocably
agrees that such amounts will not be refundable or repayable by Adimab regardless of the outcome of any proceeding resulting from
any such assertion.

 

4.6         Quarterly
Payment Timings. All royalties due under Section 4.5 (Royalties) shall be paid quarterly within ninety (90) days after
the end of the relevant calendar quarter for which royalties are due.

 

4.7         Royalty
Payment Reports. With respect to each calendar quarter, within ninety (90) days after the end of the calendar quarter, Checkpoint
shall provide to Adimab a written report stating the number and description of all Products sold during the relevant calendar quarter;
the gross sales associated with such sales; and the calculation of Net Sales on such sales, including the amount of any deduction
provided for in the definition of Net Sales. The report shall provide all such information on a country-by-country and Product-by-Product
basis.

 

4.8         Payment
Method. All payments due under this Agreement to Adimab shall be made by bank wire transfer in immediately available funds
to an account designated by Adimab. All payments hereunder shall be made in the legal currency of the United States of America,
and all references to “$” or “dollars” shall refer to United States dollars (i.e., the legal
currency of the United States).

 

4.9         Taxes.
The Parties agree to cooperate with one another and use reasonable efforts to minimize obligations for any and all income or other
taxes required by applicable law to be withheld or deducted from any royalties, milestone payments or other payments made by Checkpoint
to Adimab under this Agreement, including by completing all procedural steps, and taking all reasonable measures, to ensure that
any withholding tax is reduced or eliminated to the extent permitted under applicable law, including income tax treaty provisions
and related procedures for claiming treaty relief. To the extent that Checkpoint is required to deduct and withhold taxes on any
payment to Adimab, Checkpoint shall deduct and withhold such taxes and pay the amounts of such taxes to the proper government authority
in a timely manner and promptly submit to Adimab an official tax certificate or other evidence of such withholding sufficient to
enable Adimab to claim such payment of taxes. Checkpoint shall provide Adimab with reasonable assistance in order to allow Adimab
to recover, as permitted by applicable law, withholding taxes, value added taxes or similar obligations resulting from payments
made hereunder or to obtain the benefit of any present or future treaty against double taxation which may apply to such payments.
Adimab shall provide Checkpoint with any tax forms that may be reasonably necessary in order for Checkpoint to not withhold tax
or to withhold tax at a reduced rate under an applicable bilateral tax income treaty. Adimab shall use reasonable efforts to provide
any such tax forms to Checkpoint at least thirty (30) days prior to the due date identified by Checkpoint for any payment for which
Adimab desires that Checkpoint apply a reduced withholding rate. Checkpoint shall make all payments to Adimab from the United States.

 

    	 	18	 

     

    

 

4.10       Records;
Inspection.

 

(a)          Checkpoint
shall keep complete and accurate records of its sales and other dispositions (including use in clinical trials, or provision on
a compassionate use basis or as marketing samples) of Program Antibody and Product including all records that may be necessary
for the purposes of calculating all payments due under this Agreement.

 

(b)          At
Adimab’s expense no more than once per calendar year, Adimab has the right to retain an independent certified public accountant
from a nationally recognized (in the U.S.) accounting firm to perform on behalf of Adimab an audit, conducted in accordance with
U.S. generally accepted accounting principles (GAAP), of such books and records of Checkpoint as are deemed necessary by the independent
public accountant to report on Net Sales for the period or periods requested by Adimab and the correctness of any report or payments
made under this Agreement.

 

(c)          If
the audit reveals an underpayment, Checkpoint shall promptly pay to Adimab the amount of such undisputed underpayment plus interest
in accordance with Section 4.14 (Late Payments). If the audit reveals that the undisputed monies owed by Checkpoint to Adimab
has been understated by more than five percent (5%) for the period audited, Checkpoint shall, in addition, pay the costs of such
audit. If the audit reveals that an overpayment was made, such overpayment shall be fully creditable against amounts payable in
subsequent payment periods.

 

4.11       Licensee
Reports, Records and Audits. Any agreements with Licensees shall include an obligation for the Licensee to (i) maintain records
adequate to document and verify the proper payments (including milestones and royalties) to be paid to Adimab; (ii) provide reports
with sufficient information to allow such verification; and (iii) allow an independent certified public accountant from a nationally
recognized (in the U.S.) accounting firm appointed by Adimab to verify the payments due on behalf of Adimab.

 

4.12       Foreign
Exchange. If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such
conversion shall be made using the exchange rates reported on the fifth (5th) business day prior the payment due date for the purchase
and sale of U.S. dollars, as reported by the Wall Street Journal. With any payment in relation to which a currency conversion is
performed to calculate the amount of payment due, Checkpoint shall provide to Adimab a true, accurate and complete copy of the
exchange rates used in such calculation.

 

4.13       Non-refundable,
non-creditable payments. Each payment that is required under this Agreement is non-refundable and non-creditable except to
the extent set forth in Section 4.5(e) (Adjustment for Third Party IP).

 

4.14       Late
Payments. Any amount owed by Checkpoint to Adimab under this Agreement that is not paid within the applicable time period set
forth herein will accrue interest at the rate of four percent (4%) above the then-applicable short-term three-month London Interbank
Offered Rate (LIBOR) as quoted in the Wall Street Journal (or if it no longer exists, a similarly authoritative source) calculated
on a daily basis, or, if lower, the highest rate permitted under applicable law.

 

    	 	19	 

     

    

 

article
5

 

Intellectual Property.

 

5.1         Ownership
and Inventorship.

 

(a)          Program
Patents and Program Know-How. Adimab shall solely own, regardless of inventorship, all Program Patents directed to Adimab Platform
Technology Improvements and, prior to Option exercise, all Program Antibody Patents. Checkpoint shall own, regardless of inventorship,
from and after the date of Option exercise, those Optioned Program Antibody Patents that relate solely Optioned Antibodies and
Adimab shall own all other Optioned Program Antibody Patents, subject to the terms and conditions of this Agreement. All Program
Patents other than those referred to in the foregoing two (2) sentences shall be owned based on inventorship. Program Know-How
that constitutes Adimab Platform Technology Improvements shall be owned by Adimab and all other Program Know-How shall be owned
by the Party that created it.

 

(b)          Other
Patents. To avoid doubt, nothing in this Agreement shall alter the ownership of the Parties’ pre-existing Patents. Section
5.1(a) (Program Patents and Program Know-How) speaks only to ownership of Program Patents.

 

(c)          Inventorship.
Inventorship for purposes of this Agreement, and all intellectual property-related definitions in this Agreement, shall be determined
in accordance with United States patent law.

 

5.2          Implementation.

 

(a)          Assignments.
Each Party hereby assigns to the other Party Program Inventions, associated Patents, and Program Know-How as necessary to achieve
ownership as provided in Section 5.1 (Ownership and Inventorship). Each assigning Party shall execute and deliver all documents
and instruments reasonably requested by the other Party to evidence or record such assignment or to file for, perfect or enforce
the assigned rights. Each assigning Party hereby appoints the other Party as attorney-in-fact solely to execute and deliver the
foregoing documents and instruments if such other Party after making reasonable inquiry does not obtain them from the assigning
Party. Each Party shall perform its activities under this Agreement through personnel who have made a similar assignment and appointment
to and of such Party. Each assigning Party shall make its relevant personnel (and their assignments and signatures on such documents
and instruments) reasonably available to the other Party for assistance in accordance with this Article 5 (Intellectual Property)
at no charge.

 

(b)           Joint
Ownership Implementation. As regards Joint Serendipitous Inventions and the Program Patents to the extent claiming them, either
Party is entitled to practice and license them without consent of and without a duty of accounting to the other Party. Each Party
hereby grants all permissions, consents and waivers with respect to, and all licenses under, the Joint Serendipitous Inventions
and the Program Patents claiming them as necessary to achieve throughout the world the nature of joint ownership rights of the
foregoing as described in Section 5.1 (Ownership and Inventorship) and the foregoing sentence. To avoid doubt, this Section
5.2(b) (Joint Ownership Implementation) does not imply any permission, consent or waiver with respect to, or license under,
any Patent or item of Know-How other than the Joint Serendipitous Inventions and the Program Patents to the extent claiming them.

 

    	 	20	 

     

    

 

5.3          Disclosure.
During the term of the Agreement, each Party shall promptly disclose to the other Party the making, conception or reduction to
practice of any Program Inventions that would be Covered by Program Antibody Patents or in Checkpoint’s case that are Adimab
Platform Technology Improvements (which, to avoid doubt, are assigned to Adimab under this Agreement). Such disclosure shall occur
as soon as possible, but in any case within sixty (60) days after the Party determines such Program Inventions have been invented.
To avoid doubt, this Section 5.3 (Disclosure) shall not be read to require Adimab to disclose Program Inventions constituting
Adimab Platform Technology Improvements to Checkpoint.

 

5.4          Program
Patent Prosecution and Maintenance.

 

(a)          Adimab
Platform Technology. Adimab shall have the sole right (but not the obligation) to file, prosecute, maintain, defend and enforce
all Program Patents directed to Adimab Platform Technology Improvements and all Adimab Platform Patents, all at its own expense.

  

(b)          Program Antibody Patents. Checkpoint shall have the sole and exclusive right to file, prosecute and maintain, defend and enforce
all Program Antibody Patents, at Checkpoint’s expense, and prior to Option exercise, in Adimab’s name, and after Option
exercise, in Checkpoint’s name. Such right shall continue for the duration of the longer of the Evaluation Term and, if Checkpoint
exercises the Option, the Term. Such right shall include, following the
exercise of the Option, having the exclusive right, but not the obligation, to, at its expense, initiate, prosecute, and
control any action or legal proceedings, and/or enter into a settlement, including any declaratory judgment action, with respect
to the Program Antibody Patents. In any such litigation brought by Checkpoint with respect to the Program Antibody Patents, Checkpoint
shall have the right to join Adimab as a party to such litigation, and Adimab shall cooperate reasonably with respect thereto,
as requested by Checkpoint and at Checkpoint’s cost. The exercise of the right to file and prosecute the Program Antibody
Patents shall be subject to all of the following:

 

(i)       Prior
to Option exercise, Checkpoint shall not file any Program Antibody Patent that discloses the sequence of any Program Antibody unless
such Program Antibody Patent can be prevented from publishing.

 

(ii)      Prior
to Option exercise, to the extent that individual Program Antibodies represent distinct patentable inventions, they shall be disclosed
in separate applications and not as a group (e.g., as a filing on multiple patentable inventions), unless Adimab consents in its
discretion in writing in advance to another approach. 

 

(iii)     Both
prior to and after Option exercise, Adimab shall have the right to review and comment on prosecution of the Program Antibody Patents,
and Checkpoint shall provide Adimab with copies of all correspondence with patent offices relating thereto (including office actions
and the like) promptly after receipt and drafts of all filings and correspondence with such offices no less than 20 business days
in advance of filing.

 

(iv)     If
Checkpoint does not exercise the Option, then all Program Antibody Patents that had been filed (if any) shall be promptly
abandoned without being published and within thirty (30) days after the Option expiring Checkpoint shall make any and all filings
necessary to result in such abandonment without publication (at Checkpoint’s expense) and provide documentation thereof to
Adimab.

 

    	 	21	 

     

    

 

(v)       If
Checkpoint does exercise the Option, then all Program Antibody Patents that had been filed for such Target that disclose
Program Antibody sequences other than the sequences of Optioned Antibodies for that Target shall
be promptly abandoned without being published and within thirty (30) days after Option exercise Checkpoint shall make any and all
filings necessary to result in such abandonment without publication (at Checkpoint’s expense) and provide documentation thereof
to Adimab.

 

(vi)      Checkpoint
shall ensure that the sequences of Program Antibodies that are not Optioned Antibodies shall not become published through Program
Antibody Patents. 

 

(vii)    If
Checkpoint does exercise the Option, then Checkpoint shall prosecute
at least one Optioned Program Antibody Patent in the United States, Japan and Europe, and such other countries as are required
to be consistent with the Commercially Reasonable Efforts standard.

 

(viii)   Checkpoint
shall be solely responsible for all Checkpoint’s costs of
the activities under this Section 5.4(b) (Program Antibody Patents).

 

(c)          Responsibility.
It is understood and agreed that searching for, identification and evaluation of Third-Party Patents that may apply to any Program
Antibodies based on sequence, Target or the like is the responsibility of Checkpoint, and that Adimab shall have no responsibility
for the foregoing nor liability if any such Third-Party Patents exist.

 

(d)          Serendipitous
Program Inventions.

 

(i)       Adimab
Program Inventions. As between the Parties, Adimab shall have the sole right, at its sole expense and in its sole discretion,
to prepare, file, prosecute, enforce and maintain (including conducting or participating in interferences and oppositions) all
Patents directed to Adimab Program Inventions but not falling within the Optioned Program Antibody Patents or the Adimab Platform
Technology Improvements (which, to avoid doubt, are both addressed above).

 

(ii)      Checkpoint
Program Inventions. Checkpoint shall be responsible, at its sole expense and in its sole discretion, to prepare, file, prosecute,
enforce and maintain (including conducting or participating in interferences and oppositions) all Program Patents on Checkpoint
Program Inventions, other than Optioned Program Antibody Patents and Adimab Platform Technology Improvements (which, to avoid doubt,
are both addressed above).

 

(iii)     Serendipitous
Joint Program Inventions. The Parties shall mutually agree which of them shall be responsible for either using its in-house
patent attorneys or through mutually agreed upon outside counsel to prepare, file, prosecute, enforce and maintain Program Patents
on Joint Serendipitous Inventions, and how the costs of such activities will be shared.

 

5.5          Patent
Term Restoration. The Parties shall cooperate with each other, including by providing necessary information and assistance
as the other Party may reasonably request, to obtain patent term restoration or supplemental protection certificates or their equivalents
in any country where applicable to Patents Covering the Product. If elections with respect to obtaining such patent term restoration
are to be made with respect to such Patents, and the Parties do not agree, Checkpoint shall have the right to make the election
and Adimab agrees to abide by such election, except that if Checkpoint does not elect to extend any such Patent where it would
have been possible to do so, Checkpoint shall pay to Adimab royalties on Net Sales in the applicable country through the time until
which such Patent could have been extended, but for Checkpoint’s electing not to do so.

 

    	 	22	 

     

    

 

5.6          Cooperation
of the Parties. At the reasonable request of the responsible (as provided for in this Article 5 (Intellectual Property))
Party, the other Party agrees to cooperate fully in the preparation, filing, prosecution, enforcement and maintenance of any Program
Patents under this Agreement. Such cooperation includes executing all papers and instruments (or causing its personnel to do so)
reasonably useful to enable the other Party to apply for and to prosecute patent applications in any country; and promptly informing
the other Party of any matters coming to such Party’s attention that may affect the preparation, filing, prosecution, enforcement
or maintenance of any such Patents. Adimab shall not be required pursuant to this Section 5.6 (Cooperation of the Parties)
to disclose Adimab Platform Technology to Checkpoint.

 

article
6

 

CONFIDENTIALITY; PUBLICITY.

 

6.1         General
Confidentiality Obligations.

 

(a)          Any
and all information disclosed or submitted in writing or in other tangible form to one Party by the other Party under this Agreement
is the “Confidential Information” of the disclosing Party. In addition, information embodied in Adimab Materials
is Adimab’s Confidential Information, and information embodied in the Checkpoint Materials is Checkpoint’s Confidential
Information.

 

(b)          To
avoid doubt, sequence information (whether as to amino acid sequence or nucleic acid sequence) with respect to Program Antibodies
shall be deemed the Confidential Information of Adimab, except that from and after the date of Option exercise, the sequence information
as to the CDRs of Optioned Antibodies shall be Confidential Information of Checkpoint. For clarity, either Party shall be entitled
to disclose the non-CDRs of the Optioned Antibodies.

 

(c)          Each
Party shall receive and maintain the other Party’s Confidential Information in strict confidence. Neither Party shall disclose
any Confidential Information of the other Party to any Third Party. Neither Party shall use the Confidential Information of the
other Party for any purpose other than as required to perform its obligations or exercise its rights hereunder. Each Party may
disclose the other Party’s Confidential Information to the receiving Party’s officers, directors, employees, Affiliates,
agents, representatives and contractors requiring access thereto for the purposes of this Agreement, provided, however,
that prior to making any such disclosures, each such person shall be bound by terms at least as restrictive as those hereof to
maintain Confidential Information in confidence and not to use such information for any purpose other than in accordance with the
terms and conditions of this Agreement. Each Party agrees to take all steps necessary to ensure that the other Party’s Confidential
Information shall be maintained in confidence including such steps as it takes to prevent the disclosure of its own proprietary
and confidential information of like character. Each Party agrees that this Agreement shall be binding upon its officers, directors,
employees, Affiliates, agents, representatives and contractors involved in the Research Program. Each Party shall take all steps
necessary to ensure that its officers, directors, employees, Affiliates, agents, representatives and contractors shall comply with
the terms and conditions of this Agreement. The foregoing obligations of confidentiality and non-use shall survive, and remain
in effect for a period of five (5) years from, the termination or expiration of this Agreement in accordance with Article 9
(Term).

 

    	 	23	 

     

    

 

6.2         Exclusions
from Nondisclosure Obligation. The nondisclosure and nonuse obligations in Section 6.1 (General Confidentiality Obligations)
shall not apply to any Confidential Information to the extent that the receiving Party can establish by competent written proof
that it:

 

(a)          at
the time of disclosure is publicly known;

 

(b)          after
disclosure, becomes publicly known by publication or otherwise, except by breach of this Agreement by such Party;

 

(c)          was
in such Party’s possession at the time of the earlier of disclosure hereunder and disclosure under the agreement referred
to in Section 6.1 (General Confidentiality Obligations);

 

(d)           is
received by such Party from a Third Party who has the lawful right to disclose the Confidential Information and who shall not have
obtained the Confidential Information either directly or indirectly from the disclosing Party; or

 

(e)           is
independently developed by such Party (i.e., without reference to Confidential Information of the disclosing Party).

 

6.3          Required
Disclosures. If either Party is required, pursuant to a governmental law, regulation or order, to disclose any Confidential
Information of the other Party, the receiving Party (i) shall give advance written notice to the disclosing Party, (ii) shall
make a reasonable effort to assist the other Party to obtain a protective order requiring that the Confidential Information so
disclosed be used only for the purposes for which the law or regulation required and (iii) shall use and disclose the Confidential
Information solely to the extent required by the law or regulation.

 

6.4          Terms
of Agreement. The terms of this Agreement are the Confidential Information of both Parties. However, each Party shall be entitled
to disclose the terms of this Agreement under legally binding obligations of confidence and limited use to: legal, financial and
investment banking advisors; and potential and actual investors, acquirers and licensees or sublicensees doing diligence and counsel
for the foregoing. In addition, if legally required, a copy of this Agreement may be filed by either Party with the SEC (or relevant
ex-U.S. counterpart). In that case, the filing Party will if requested by the other Party diligently seek confidential treatment
for terms of this Agreement for which confidential treatment is reasonably available, and shall provide the non-filing Party reasonable
advance notice of the terms proposed for redactions and a reasonable opportunity to request that the filing Party make additional
redactions to the extent confidential treatment is reasonably available under the law. The filing Party shall seek and diligently
pursue such confidential treatment requested by the non-filing Party.

 

    	 	24	 

     

    

 

6.5          Return
of Confidential Information. Promptly after the termination or expiration of this Agreement for any reason, each Party shall
return to the other Party all tangible manifestations of such other Party’s Confidential Information at that time in the
possession of the receiving Party.

 

6.6          Publicity.
Either Party may make an initial press release announcing the execution of this Agreement, but such Party shall provide the text
of such planned disclosure to the other Party sufficiently in advance of the scheduled disclosure to afford such other Party reasonable
opportunity to review and comment upon the proposed text and the timing of such disclosure, and shall consider all reasonable comments
of the other Party regarding such disclosure; provided, however, that no Party shall use the trademark or logo of the other
Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or public disclosure relating to
this Agreement or its subject matter, except as may be required by Law or required by the rules of an applicable US national securities
exchange or except with the prior express written permission of such other Party, such permission not be unreasonably withheld.
Other than repeating information in any mutually agreed press release, neither Party will generate or allow any further publicity
regarding this Agreement or the transaction or research contemplated hereunder in which the other Party is identified, without
giving the other Party the opportunity to review and comment on the press release. The Parties recognize the importance of announcing
Option and the achievement of Milestones, and that Adimab is entitled to disclose these occurrences. Accordingly, the Parties hereby
agree that each such event shall be publicly announced by the Parties if requested by Adimab, and the Parties shall mutually agree
upon the text of a press release to announce each such event. Checkpoint shall not unreasonably withhold its consent to the manner
in which Adimab proposes to make such disclosure. It is understood and agreed that Adimab sometimes issues press releases that
group multiple achievements of the company, and that if Adimab chooses to group the initially approved text or the announcement
of Option exercise and/or a milestone achievement under this Agreement with other accomplishments or events not relating to this
Agreement, then the only portion of the press release into which the Checkpoint shall have a consent right (such consent not to
be unreasonably withheld), shall be those portions that relate to this Agreement.

 

6.7         Certain
Data. Notwithstanding this Article 6 (Confidentiality; Publicity), without disclosing Checkpoint’s identity or
the identity of the Target (although the class of protein of the Target may be disclosed), or the sequence of any Program Antibody,
in order to describe the general capabilities and performance of the Adimab platform, Adimab shall be entitled to disclose generally
Program Antibody attributes and Program Know-How, including the following: (a) Program Antibody binding affinities (KD),
(b) expression range regarding Program Antibodies, and (c) germline distribution of Program Antibodies.

 

article
7

 

REPRESENTATIONS AND
WARRANTIES.

 

7.1         Mutual
Representations. Each of Adimab and Checkpoint hereby represents and warrants to the other of them that the representing and
warranting Party is duly organized in its jurisdiction of incorporation; that the representing and warranting Party has the full
power and authority to enter into this Agreement; that this Agreement is binding upon the representing and warranting Party; that
this Agreement has been duly authorized by all requisite corporate action within the representing and warranting Party; and that
the execution, delivery and performance by the representing and warranting Party of this Agreement and its compliance with the
terms and conditions hereof does not and shall not conflict with or result in a breach of any of the terms and conditions of or
constitute a default under (a) any agreement or other instrument binding or affecting it or its property, (b) the provisions of
its bylaws or other governing documents or (c) any order, writ, injunction or decree of any governmental authority entered against
it or by which any of its property is bound.

 

    	 	25	 

     

    

 

7.2          Representations
of Adimab. Adimab. Adimab hereby represents, warrants and covenants
to Checkpoint that, as of the Effective Date:

 

(a)          There
are no complaints filed in court or, to Adimab’s knowledge, otherwise threatened, in each case pending relating to Adimab
Platform Patents which, if decided in a manner adverse to Adimab, would materially affect Adimab’s practice of the Adimab
Platform Technology as contemplated by this Agreement.

 

(b)          There
are no judgments or settlements against Adimab or its Affiliates or to which they are Party which will materially affect Adimab’s
practice of the Adimab Platform Technology as contemplated in this Agreement. Adimab is not party to any settlement discussions
that, if concluded as of the Effective Date, would result in a settlement which would materially affect Adimab’s practice
of the Adimab Platform Technology as contemplated in this Agreement.

 

(c)          To
Adimab’s knowledge, the conception, development and reduction to practice of the Adimab Platform Technology, as it exists
on the Effective Date, have not constituted or involved the misappropriation of trade secrets, know-how or similar rights or property
of any person.

 

(d)          In
Adimab’s reasonable judgment, the practice of the Adimab Platform Technology as practiced by Adimab as of the Effective Date,
does not infringe a valid, issued Patent owned by a Third Party of which Adimab has knowledge.

 

(e)          Adimab
has the right to grant to Checkpoint the licenses set forth in Section 3.1 and 3.2;

 

(f)           Notwithstanding
the foregoing, Adimab specifically excludes any representations with respect to any Excluded
Technology.

 

7.3         DISCLAIMER
OF WARRANTIES. OTHER THAN THE EXPRESS WARRANTIES OF SECTION 7.1 (MUTUAL REPRESENTATIONS) AND SECTION 7.2 (REPRESENTATIONS OF
ADIMAB), Each party DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT ANY PRODUCTS DEVELOPED UNDER THIS AGREEMENT ARE FREE
FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE OR THAT ANY PROGRAM PATENTS WILL ISSUE OR BE VALID
OR ENFORCEABLE.

 

    	 	26	 

     

    

 

article
8

 

INDEMNIFICATION

 

8.1          Indemnification
by Adimab. Adimab hereby agrees to indemnify, defend and hold harmless (collectively, “Indemnify”) Checkpoint,
its Affiliates and its and their directors, officers, agents and employees (collectively, “Checkpoint Indemnitees”)
from and against any and all liability, loss, damage or expense (including without limitation reasonable attorneys’ fees)
(collectively, “Losses”) they may suffer as the result of Third-Party claims, demands and actions (collectively,
“Third-Party Claims”) arising out of or relating to (a) any breach of a representation or warranty made by Adimab
under Article 7 (Representations and Warranties), (b) Checkpoint’s use of any Adimab’s Materials (other
than Program Antibodies), (c) following termination of this Agreement pursuant to Section 9.2, Adimab’s, or its Affiliates’
or Licensees’ research, testing, development, manufacture, use, sale, distribution, licensing and/or commercialization of
Program Antibodies and/or Products (or Program-Benefited Antibodies or products incorporating them) and (d) contractual obligations
of Adimab and its Affiliates, except in each case to the extent of any Losses (i) attributable to the negligence or intentional
misconduct of any Checkpoint Indemnitee, or (ii) arising out of any breach of a representation or warranty made by Checkpoint
in Article 7 (Representations and Warranties).

 

8.2          Indemnification
by Checkpoint. Checkpoint hereby agrees that it and its Licensees shall Indemnify Adimab, its Affiliates and its and their
directors, officers, agents and employees (collectively, “Adimab Indemnitees”) from and against any and all
Losses they may suffer as the result of Third-Party Claims arising out of or relating to (a) any breach of a representation
or warranty made by Checkpoint under Article 7 (Representations and Warranties), (b) Checkpoint’s research,
testing, development, manufacture, use, sale, distribution, licensing and/or commercialization of Program Antibodies and/or Products
(or Program-Benefited Antibodies or products incorporating them), (c) Adimab’s use of any Checkpoint Materials, (d) the use
by Checkpoint or its Licensees of any Excluded Technology, and (e) contractual obligations of Checkpoint and its Affiliates, except
in each case to the extent of any Losses (i) attributable to the negligence or intentional misconduct of any Adimab Indemnitee,
or (ii) arising out of any breach of a representation or warranty made by Adimab in Article 7 (Representations and Warranties).

 

8.3          Indemnification
Procedures. Each of the foregoing agreements to Indemnify is conditioned on the relevant Adimab Indemnitees or Checkpoint Indemnitees
(i) providing reasonable assistance in the defense of such claim at the indemnifying Party’s reasonable expense, and (ii) not
compromising or settling such Third-Party Claim without the indemnifying Party’s advance written consent. If the Parties
cannot agree as to the application of the foregoing Sections 8.1 (Indemnification by Adimab) and 8.2 (Indemnification
by Checkpoint), each may conduct separate defenses of the Third-Party Claim, and each Party reserves the right to claim indemnity
from the other in accordance with this Article 8 (Indemnification) upon the resolution of the underlying Third-Party Claim.

 

8.4         Limitation
of Liability. EXCEPT TO THE EXTENT SUCH PARTY MAY BE REQUIRED TO INDEMNIFY THE OTHER PARTY UNDER THIS ARTICLE 8 (INDEMNIFICATION)
OR AS REGARDS A BREACH OF A PARTY’S RESPONSIBILITIES PURSUANT TO ARTICLE 6 (CONFIDENTIALITY; PUBLICITY), NEITHER PARTY NOR
ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES HEREUNDER, WHETHER
IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE.

 

    	 	27	 

     

    

 

article
9

 

TERM.

 

9.1         Term.
The term of this Agreement shall commence on the Effective Date and shall expire upon (a) in the event that no Option is exercised,
the conclusion of the last-to-expire Evaluation Term; or (b) in the event that an Option is exercised, on a country-by-country
and Product-by-Product basis on the expiration of the last Royalty Term for a Product in the particular country, in each case,
unless earlier terminated by a Party as set forth below in this Article 9 (Term).

 

9.2          Material
Breach. Either Party may terminate this Agreement for the material
breach of this Agreement by the other Party, if such breach remains uncured ninety (90) days following notice from the non-breaching
Party to the breaching Party specifying such breach. 

 

9.3          Commitments
Regarding Program-Benefited Antibodies. If Checkpoint or any of its Licensees researches, develops, manufactures, or commercializes
any Program-Benefited Antibody, they shall pay fees to Adimab as provided in Article 4 (Financial Terms), including the Option
Fee, Milestone Payments and Royalty Payments, as applicable, on the Program-Benefited Antibody as (or as if) a Product under this
Agreement. In the event that Checkpoint is unwilling or unable to pay such fees to Adimab (because, for example, of the dissolution
of Checkpoint for bankruptcy or other reasons), then each Licensee shall make such payments directly to Adimab. If this Agreement
expires or terminates (other than an expiration under Section 9.1 following an Option exercise after all applicable Royalty Terms
have expired), Checkpoint and its Licensees (a) shall not research, develop or commercialize any Program-Benefited Antibody or
Product containing such an antibody except as a Product under this Agreement, (b) shall not license or otherwise grant rights to
any entity to do the foregoing, and (c) shall not practice, license or assign to a Third Party, option to a Third Party or covenant
not to sue a Third Party with respect to Program Antibody Patents (regardless of inventorship), Program-Benefited Antibodies, or
products containing them.

 

9.4         Survival
in All Cases. Termination of this Agreement shall be without prejudice to or limitation on any other remedies available to
nor any accrued obligations of either Party. In addition, Sections 2.3 (Reports; Records), 2.4 (Use of Adimab Materials),
2.5 (Use of Checkpoint Materials), 2.6 (Certain Restrictions on the Use of Antibodies), 3.4 (No Implied Licenses),
3.5 (Covenant Not to Exceed License), 4.6 (Quarterly Payment Timings) through 4.14 (Late Payments) (with respect
to payment obligations outstanding or having accrued as the effective date of termination or expiration), 5.1 (Ownership and
Inventorship), 5.2 (Implementation), 5.4 (Program Patent Prosecution and Maintenance), 5.6 (Cooperation of
the Parties), and 7.3 (Disclaimer of Warranties), and Articles 1 (Definitions), 6 (Confidentiality; Publicity),
8 (Indemnification), 9 (Term) and 10 (Miscellaneous) shall survive any expiration or termination of this Agreement.

 

9.5         Return
of Adimab Materials. Checkpoint shall either return to Adimab or destroy all Adimab Materials (other than Adimab Materials
relating to Optioned Antibodies) Target upon expiration or termination of the Evaluation Term without the Option being exercised,
and all Adimab Materials on expiration or termination of this Agreement.

 

    	 	28	 

     

    

 

9.6         Additional
Effects of Termination. If Adimab terminates this Agreement pursuant to Section 9.2 for Checkpoint’s uncured material
breach, then : (a) Checkpoint and its Affiliates would assign to Adimab all right, title and interest in and to the Program Patents,
Program Know-How, all data with respect to Program-Benefited Antibodies, and all producing cell lines for Program-Benefited Antibodies
(the “Program Assets”); (b) Checkpoint and its Affiliates would transfer such cell lines to Adimab (under conditions
intended to ensure their viability) along with all master batch records and SOPs for production of such antibodies (the “Tangible
Assets”); (c) Checkpoint and its Affiliates would transfer all filings with regulatory authorities with respect to Program-Benefited
Antibodies to Adimab if Adimab so requests (the “Regulatory Assets” and, together with the Program Assets and
Tangible Assets, the “Transferred Assets”); and (d) Adimab shall pay Checkpoint a royalty equal based on the
date of termination of this Agreement as set forth below.

 

	Effective Date of Termination	Royalty Rate
	 	 
	*	*
	 	 
	*	*
	 	 
	*	*
	 	 

 

For purposes of this
Section 9.6 (Additional Effects of Termination), Sections 4.5 (Royalties) through 4.14 (Late Payments), the
definition of Net Sales and all other defined terms (including their respective definitions) in such Sections shall apply mutatis
mutandis to the Adimab’s obligations to pay royalties under this Section 9.6 and each reference in each such Section (and
any related definitions) to (i) Adimab shall be deemed to be a reference to Checkpoint, (ii) Checkpoint shall be deemed to be a
reference to Adimab and (iii) a Licensee shall be deemed to be a reference to a licensee or sublicensee of Adimab or any of its
Affiliates with respect to the Product. Any license of any Transferred Assets shall be made solely pursuant to written agreements
(“License Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees
who explicitly agree in writing to comply with all applicable terms of this Agreement. Adimab shall remain responsible for all
payments and other performance obligations due under this Section 9.6 (Additional Effects of Termination), notwithstanding
any license that it may grant. Adimab shall not (i) assign or transfer the Transferred Assets (in whole or in part) to any third
party unless (a) such transfer or assignment is pursuant to a binding written agreement pursuant to which such third party to be
bound by the terms of this Section 9.6 (Additional Effects of Termination)and (b) such agreement provides that Checkpoint
is a third party beneficiary thereof for the purposes of enforcing its rights under this Section 9.6 and (ii) take any action avoid
the payment obligations under this Section 9.6 (Additional Effects of Termination) or to circumvent or frustrate the purposes
of this Section 9.6 (Additional Effects of Termination). Checkpoint shall not (i) assign or transfer the Program-Benefited
Antibodies or Products (in whole or in part) to any third party unless (a) such transfer or assignment is pursuant to a binding
written agreement pursuant to which such third party to be bound by the terms of Article 4 (Financial Terms) and (b) such
agreement provides that Adimab is a third party beneficiary thereof for the purposes of enforcing its rights under Article 4 (Financial
Terms) and (ii) take any action avoid the payment obligations under this Agreement or to circumvent or frustrate the purposes
of Article 4 (Financial Terms).

 

 

		*	Confidential material redacted and filed separately with
the Commission.

 

    	 	29	 

     

    

 

9.7         Survival
of Sublicenses. Notwithstanding any provision herein to the contrary, in the event (a) Checkpoint has entered into any Sublicense
Agreements consistent with the terms of this Agreement, (b) this Agreement is terminated, and (c) such Sublicense Agreements are
in effect at the time of such termination, such Sublicense Agreement will survive such termination, with Adimab as the Licensee’s
direct licensor solely with respect to rights sublicensed pursuant to this Agreement, provided that the Licensee pays all amounts
due hereunder with respect to its exercise of rights regarding Optioned Antibodies.

 

article
10

 

MISCELLANEOUS.

 

10.1       Independent
Contractors. The Parties shall perform their obligations under this Agreement as independent contractors. Nothing contained
in this Agreement shall be construed to be inconsistent with such relationship or status. This Agreement and the Parties’
relationship in connection with it shall not constitute, create or in any way be interpreted as a joint venture, fiduciary relationship,
partnership or agency of any kind.

 

10.2       Dispute
Resolution.

 

(a)          Initial
Dispute Resolution. Either Party may refer any dispute in connection with this Agreement (“Dispute”) not
resolved by discussion of the BD/Contract Liaisons to senior executives of the Parties (for Adimab, its CEO or his designee and
for Checkpoint, its CEO or his designee) for good-faith discussions over a period of not less than sixty (60) days (the “Senior
Executives Discussions”). Each Party will make its executives reasonably available for such discussions.

 

(b)          Disputes
Not Resolved Between the Parties. If the Parties are unable to resolve the dispute through the Senior Executives Discussions
within such sixty (60) days, then either Party may, as the sole and exclusive means for resolving disputes under this Agreement,
proceed to demand confidential arbitration by written notice to the other Party and making a filing with the AAA in accordance
with Section 10.2(c) (Arbitration). For clarity, each Party hereby acknowledges that both the fact of and nature of a dispute
is the Confidential Information of both Parties, and any disclosure of the fact of or the nature of such a dispute would be highly
damaging to the non-disclosing Party.

 

(c)          Arbitration.

 

(i)       Any
Dispute referred for arbitration shall be finally resolved by binding arbitration in accordance with the most applicable rules
of the American Arbitration Association (“AAA”) and judgment on the arbitration award may be entered in any
court having jurisdiction.

 

(ii)       The
arbitration shall be conducted by a panel of three (3) people experienced in the business of biopharmaceuticals. If the issues
in dispute involve scientific, technical or commercial matters, then any arbitrator chosen under this Agreement shall have educational
training and/or industry experience sufficient to demonstrate a reasonable level of relevant scientific, technical and commercial
knowledge as applied to the pharmaceutical industry. If the issues in dispute involve patent matters, then at least one (1) of
the arbitrators shall be a licensed patent attorney or otherwise knowledgeable about patent law matters. Within thirty (30) days
after a Party demands arbitration, each Party shall select one person to act as arbitrator, and the two Party-selected arbitrators
shall select a third arbitrator within thirty (30) days after their own appointment. If the arbitrators selected by the Parties
are unable or fail to agree upon the third arbitrator, then the third arbitrator shall be appointed by the AAA. The place of arbitration
shall be New York, NY. All proceedings and communications as part of the arbitration shall be in English. Following selection of
the third arbitrator, the arbitrators shall complete the arbitration proceedings and render an award within six (6) months after
the last arbitrator is appointed.

 

    	 	30	 

     

    

 

(iii)       Each
Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any
administrative fees or arbitration, unless in each case the arbitrators agree otherwise, which they are hereby empowered, authorized
and instructed to do if they determine that to be fair and appropriate.

 

(iv)       Except
to the extent necessary to confirm an award or as may be required by law, regulation, or the requirement of any exchange on which
a Party’s shares are traded, neither Party shall disclose the existence, content or results of an arbitration under this
Agreement without the prior written consent of the other Party.

 

(v)       In
no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the subject
matter of the Dispute would be barred by the applicable statute of limitations under New York law.

 

10.3       Governing
Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding its
conflicts of laws principles.

 

10.4       Entire
Agreement. This Agreement (including its Exhibits) set forth all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties with respect to the subject matter hereof and supersedes and terminates all prior
agreements and understandings between the Parties with respect to such subject matter. No subsequent alteration, amendment, change
or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized
officers of the Parties.

 

10.5       Assignment.
Neither Party may assign in whole or in part this Agreement without the advance written consent of the other Party, except as set
forth in the following sentence. Either Party may assign this Agreement in its entirety to an Affiliate at any time or to a successor
to all or substantially all of its stock or assets to which this Agreement relates in connection with its merger with, or the sale
of all or substantially all of its stock or assets to which this Agreement relates to, another entity, regardless of the form of
the transaction. In addition, Adimab may assign this Agreement or any of its rights under this Agreement, in connection with the
sale of, monetization of, transfer of, or obtaining financing on the basis of the payments due to Adimab under this Agreement or
debt or project financing in connection with this Agreement; provided, however, that in such case Adimab shall remain liable
for the performance of all of its assignee’s obligations hereunder as if Adimab has not assign this Agreement. This Agreement
shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. Notwithstanding
the foregoing, Adimab may not assign or otherwise transfer (by operation of law or otherwise) this Agreement if the assignee does
not assume all of Adimab’s obligations under this Agreement or Adimab does not remain bound to perform all obligations that
are not assigned to the assignee. Any assignment of this Agreement not made in accordance with this Agreement is prohibited hereunder
and shall be null and void.

 

    	 	31	 

     

    

 

10.6       Severability.
If one or more of the provisions in this Agreement are deemed unenforceable by law, then such provision shall be deemed stricken
from this Agreement and the remaining provisions shall continue in full force and effect.

 

10.7       Force
Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such
performance is prevented by a Force Majeure and the nonperforming Party promptly provides notice of the prevention to the other
Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party
takes reasonable efforts to remove the condition, but no longer than six (6) months. For purposes of this Agreement,

 

10.8       Notices.
Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement
and shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail, postage
prepaid, delivered by express delivery service or personally delivered. Unless otherwise specified in writing, the mailing addresses
of the Parties shall be as described below.

 

If to Adimab:

 

Adimab, LLC

7 Lucent Drive

Lebanon, NH 03766

Attention: General Counsel

 

with a required copy to:

 

Attention: Head, Business Development at the same
address.

 

In the case of Checkpoint:

 

Checkpoint Therapeutics, Inc.

2 Gansevoort Street, 9th
Floor

New York, NY 10014

Attn: CEO

 

10.9       Construction.
This Agreement has been prepared jointly and shall not be strictly construed against either Party. Ambiguities, if any, in this
Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

 

10.10      Headings.
The headings for each article and section in this Agreement have been inserted for convenience of reference only and are not intended
to limit or expand on, nor to be used to interpret, the meaning of the language contained in the particular article or section.

 

10.11      No
Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other
matter shall not constitute a waiver of such Party’s rights to the subsequent enforcement of its rights under this Agreement,
excepting only as to an express written and signed waiver as to a particular matter for a particular period of time executed by
an authorized officer of the waiving Party.

 

    	 	32	 

     

    

 

10.12     Performance
by Affiliates. A Party may perform some or all of its obligations under this Agreement through Affiliate(s) or may exercise
some or all of its rights under this Agreement through Affiliates. However, each Party shall remain responsible and be guarantor
of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection
with such performance as if such Party were performing such obligations itself, and references to a Party in this Agreement shall
be deemed to also reference such Affiliate. In particular and without limitation, all Affiliates of a Party that receive Confidential
Information of the other Party pursuant to this Agreement shall be governed and bound by all obligations set forth in Article 6
(Confidentiality; Publicity), and shall (to avoid doubt) be subject to the intellectual property assignment and other intellectual
property provisions of Article 5 (Intellectual Property) as if they were the original Party to this Agreement (and be deemed
included in the actual Party to this Agreement for purposes of all intellectual property-related definitions). A Party and its
Affiliates shall be jointly and severally liable for their performance under this Agreement.

 

10.13     Counterparts.
This Agreement may be executed in one or more identical counterparts, each of which shall be deemed to be an original, and which
collectively shall be deemed to be one and the same instrument. In addition, signatures may be exchanged by facsimile or PDF.

 

[Remainder
of Page Left Intentionally Blank; Signature Page Follows]

 

    	 	33	 

     

    

 

In
Witness Whereof, the Parties have by duly authorized persons executed this Agreement as of the Effective Date.

 

	Checkpoint Therapeutics, Inc.:	 	Adimab, LLC:
	 	 	 	 	 
	By:	/s/ James F. Oliviero	 	By:	/s/ Tillman U. Gerngross
	 	 	 	 	 
	Title:	CEO	 	Title:	CEO
	 	 	 	 	 
	Date:	1/22/2019	 	Date:	1/22/2019

 

    	 	34Exhibit 10.35

 

FIRST AMENDMENT,
WAIVER AND CONSENT TO CREDIT AGREEMENT

 

This FIRST AMENDMENT,
WAIVER AND CONSENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of March [ ], 2019
by and among Workhorse Group Inc., a Nevada corporation (the “Borrower”), Wilmington Trust, National Association,
in its capacity as agent (the “Agent”), and the Lenders (as defined below) party hereto.

 

WHEREAS, the Borrower,
the financial institutions from time to time party thereto as lenders (collectively, with their permitted successors and assignees,
the “Lenders”), and the Agent are party to that certain Credit Agreement, dated as of December 31, 2018 (the
“Credit Agreement”), pursuant to which the Lenders have extended credit to the Borrower on the terms set forth
therein;

 

WHEREAS,
pursuant to Section 10.1 of the Credit Agreement, the Credit Agreement may be amended by an instrument in writing signed by the
Borrower and the Lenders; and

 

WHEREAS,
the Borrower and the Lenders desire to (i) amend certain provisions of the Credit Agreement and (ii) confirm the Lenders’
consent to the replacement of the Borrower’s chief executive officer and chief operating officer, in each case as provided
in this Amendment.

 

NOW, THEREFORE,
in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                 
Definitions; Loan Document. Capitalized terms used herein without definition shall have the meanings assigned
to such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement
and the other Loan Documents.

 

2.                 
Amendments to Section 1.1. The following definitions
in Section 1.1 of the Credit Agreement are hereby amended and restated as follows:

 

“Interest
Payment Date” means the fifth calendar day of January, April, July and October; provided that, for the avoidance
of doubt, the Lenders shall not have waived or be deemed to have waived the first payment of interest due under this Agreement,
which payment of interest shall be due and payable on April 5, 2019.

 

    1 

     

    

  

“LIBOR”
means, with respect to any Loan for any Interest Period, the London interbank offered rate as administered by the ICE Benchmark
Administration (or any other Person that takes over the administration of such rate) for Dollars for a period equal in length
to such Interest Period as displayed on page LIBOR01 or LIBOR02 of the Reuters Screen that displays such rate (or, in the event
such rate does not appear on a Reuters page or screen, on any successor or substitute page on such screen that displays such rate,
or on the appropriate page of such other information service that publishes such rate from time to time as selected by the Agent
(at the direction of the Required Lenders) in its reasonable discretion; in each case, the “Screen Rate”) at
approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period; provided that,
notwithstanding anything to the contrary in the foregoing, LIBOR with respect to the initial Interest Period of any Tranche Two
Loan (other than any Tranche Two Loan which has the same Interest Period as the Tranche One Loans) shall be deemed to be LIBOR
as in effect for the other Loans outstanding hereunder immediately prior to the borrowing of such Tranche Two Loan; provided
further that, if the Screen Rate shall not be available at such time for such Interest Period (an “Impacted Interest
Period”) with respect to Dollars, then the LIBOR Rate shall be the Interpolated Rate at such time.  For purposes
hereof, “Interpolated Rate” means, at any time, the rate per annum determined by the Agent (at the direction
of the Required Lenders) (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that
results from interpolating on a linear basis between: (a) the Screen Rate for the longest period (for which that Screen Rate is
available in Dollars) that is shorter than the Impacted Interest Period and (b) the Screen Rate for the shortest period (for which
that Screen Rate is available for Dollars) that exceeds the Impacted Interest Period, in each case, at such time.

 

3.                 
Amendment to Section 2.3.1. Section 2.3.1(b) of the Credit Agreement is hereby amended and restated as follows:

 

“(b)The Borrower
promises to pay interest on the full amount of the Unused Tranche Two Commitment and the unpaid principal amount of the outstanding
Tranche Two Loans for the period commencing on the Closing Date and ending on (and including) the date on which the Tranche Two
Loans are Paid in Full and the Tranche Two Commitment is terminated, at the Applicable Contract Rate. For the avoidance of doubt,
(i) interest paid on the Unused Tranche Two Commitment shall be the same amount of interest that would be paid on a Tranche Two
Loan in the same principal amount as the amount of such Unused Tranche Two Commitment and (ii) the interest rate applicable to
the Unused Tranche Two Commitment will adjust concurrently with any adjustment of the interest rate applicable to the Tranche Two
Loans.”

 

4.                 
Amendment to Section 6.1.1. Section 6.1.1 of the Credit Agreement is hereby amended by replacing “which
opinion shall not be qualified” therein with “which opinion, beginning with the financial statements for the Fiscal
Year ending December 31, 2019, shall not be qualified”.

 

5.                 
Amendment to Section 6.15. Sections 6.15(a)(ii)-(iii)
and 6.15(a)(v) of the Credit Agreement are each hereby amended by deleting each reference to “30 days” and replacing
each such reference with “90 days”.

 

6.                 
Waiver. The Lenders hereby waive any Defaults or Events of Default due to any non-compliance or breach by
the Borrower of Section 6.15 or Section 7.17 of the Credit Agreement, each such section as in effect immediately prior to the effectiveness
of this Amendment.

 

7.                 
Confirmation of Consent. The Lenders hereby confirm their consent to (i) the replacement, by Duane Hughes,
of Stephen Burns as chief executive officer of the Borrower and (ii) the replacement, by Robert H. Willison, of Duane Hughes as
chief operating officer and president of the Borrower.

 

    2 

     

    

  

8.                 
Conditions to Effectiveness of Amendment. This Amendment shall become effective upon receipt by the Agent
and the Lenders of counterpart signatures to this Amendment duly executed and delivered by the Agent, the Lenders and the Borrower.

 

9.                 
Expenses. The Borrower agrees to pay on demand all expenses of the Lender (including, without limitation,
the fees and out-of-pocket expenses of Covington & Burling LLP, counsel to the Lenders, and Duane Morris LLP, counsel to the
Agent) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment.

 

10.             
Representations and Warranties. The Borrower represents and warrants to the Lenders and the Agent as follows:

 

(a)              
After giving effect to this Amendment, the representations and warranties of the Loan Parties contained in the Credit Agreement
or any other Loan Document shall be true and correct in all material respects (without duplication of any materiality qualifier
contained therein) as of the date hereof (or as of a specific earlier date if such representation or warranty expressly relates
to an earlier date).

 

(b)              
After giving effect to this Amendment, no Default or Event of Default under the Credit Agreement is continuing.

 

11.             
No Implied Amendment or Waiver. Except as expressly set forth in this Amendment, this Amendment shall not,
by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Agent or the
Lenders under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms,
obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force
and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of the Agent or the Lenders to agree
to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the
other Loan Documents.

 

    3 

     

    

  

12.             
Release. The Borrower hereby acknowledges and agrees that: (a) to its knowledge neither it nor any of its
Affiliates have any claim or cause of action against any Lender or the Agent (or any of their respective Affiliates, officers,
directors, employees, attorneys, consultants or agents) under the Credit Agreement as of the date hereof and (b) to its knowledge,
as of the date hereof, the Lenders and the Agent have heretofore properly performed and satisfied in a timely manner all of their
respective obligations to the Borrower under the Credit Agreement. Notwithstanding the foregoing, the Agent and the Lenders wish
to eliminate any possibility that any past conditions, acts, omissions, events or circumstances would impair or otherwise adversely
affect any of the Agent’s or the Lenders’ rights, interests and/or remedies under the Credit Agreement. Accordingly,
for and in consideration of the agreements contained in this Amendment and other good and valuable consideration, the Borrower
(for itself and its Affiliates and the successors and assigns of each of the foregoing) (each a “Releasor” and
collectively, the “Releasors”) does hereby fully, finally, unconditionally and irrevocably release and forever
discharge the Agent and the Lenders and each of their respective Affiliates, officers, directors, employees, attorneys, consultants
and agents (each a “Released Party” and collectively, the “Released Parties”) from any and
all debts, claims, obligations, damages, costs, attorneys’ fees, suits, demands, liabilities, actions, proceedings and causes
of action, in each case, whether known or unknown, contingent or fixed, direct or indirect, and of whatever nature or description,
and whether in law or in equity, under contract, tort, statute or otherwise, in each case that exist or have occurred on or prior
to the date of this Amendment which any Releasor has heretofore had or now shall or may have against any Released Party by reason
of any act, omission or thing whatsoever done or omitted to be done, except for a Released Party’s gross negligence or willful
misconduct as determined by a final, nonappealable judgment of a court of competent jurisdiction, prior to the date hereof arising
out of, connected with or related in any way to the Credit Agreement, or any act, event or transaction related or attendant thereto,
or the Agent’s or the Lenders’ agreements contained therein, or the possession, use, operation or control in connection
therewith of any of the assets of the Borrower, or the making of any advance thereunder, or the management of such advance, in
each case on or prior to the date of this Amendment.

 

13.             
Counterparts. This Amendment may be executed by the parties hereto in several counterparts, each of which
shall be an original and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart
of a signature page of this Amendment by e-mail (e.g., “pdf” or “tiff”) or fax transmission shall be effective
as delivery of a manually executed counterpart of this Amendment.

 

14.             
Governing Law. THIS AMENDMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE
OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PREPARED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES
(OTHER THAN SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).

 

[Remainder
of Page Intentionally Left Blank.]

 

 

    4 

     

    

  

IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year
first above written.

 

	WORKHORSE GROUP INC.

as the Borrower

	 	 
	By:	  	 
	Name:	 	 
	Title:	 	 

 

	MARATHON STRUCTURED PRODUCT STRATEGIES FUND, LP

MARATHON BLUE GRASS CREDIT FUND, LP

MARATHON CENTRE STREET PARTNERSHIP, L.P.

TRS CREDIT FUND, LP
 as Lenders

 

By: Marathon Asset Management LP, the investment advisor to each of the entities listed above

	 	 
	By:	 	 
	Name:	Louis Hanover	 
	Title:	CIO, Co-Managing Partner	 

 

	WILMINGTON TRUST, NATIONAL ASSOCIATION
 as the Agent

	 	 
	By:	 	 
	Name:	Jamie Roseberg	 
	Title:	Banking Officer	 

 

 

 

Signature Page to First Amendment, Waiver
and Consent to Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]